



Clinical trial results:

Evaluation of tolerance, suckling and food intake after repeated nasals administrations of Oxytocin in PWS infants

Summary

EudraCT number	2012-005325-67
Trial protocol	FR
Global end of trial date	15 July 2014

Results information

Result version number	v1 (current)
This version publication date	28 December 2023
First version publication date	28 December 2023

Trial information

Trial identification

Sponsor protocol code	1239102
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02205034
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	CHU de Toulouse
Sponsor organisation address	2 rue viguerie, Toulouse, France, 31059
Public contact	Nadège ALGANS, CHU de Toulouse, +33 056177204, algans.n@chu-toulouse.fr
Scientific contact	Maïthé TAUBER, CHU de Toulouse, +33 0534558551, tauber.m@chu-toulouse.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-003148-PIP01-21
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 June 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 July 2014
Global end of trial reached?	Yes
Global end of trial date	15 July 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To study tolerance of oxytocin repeated nasal administrations during 7 days (according to 3 plans of administration) to babies with Prader Willi Syndrom younger than 5 months.

Protection of trial subjects:

A monitoring committee composed of the investigating physicians and a representative of the Research Department will meet every 6 months for the duration of the study. It will be in charge of analyzing the data, in particular the tolerance data, and of considering the course of action in case of repeated serious adverse events not related a priori to oxytocin.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 May 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects**Subjects enrolled per country**

Country: Number of subjects enrolled	France: 18
Worldwide total number of subjects	18
EEA total number of subjects	18

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	18
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Children were recruited into the study as part of their disease caring. The study was proposed by the investigating physician to the representatives of the parental authority so that the children can be included in the study.

Pre-assignment

Screening details:

The investigating physician has given information about the study to the representatives of the child's parental authority within 10 days prior to inclusion and answered all their questions concerning the objective, the nature of the constraints, the foreseeable risks and the expected benefits of the research and verified the inclusion criteria

Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	arm 1 : 4UI every 2 days

Arm description:

children received 4UI of OT per day

Arm type	Experimental
Investigational medicinal product name	Oxytocin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal drops, solution
Routes of administration	Intranasal use

Dosage and administration details:

4 UI per day

Arm title	arm2 : 4 UI/day
------------------	-----------------

Arm description:

children received 4UI/day of Oxytocin

Arm type	Experimental
Investigational medicinal product name	Oxytocin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal drops, solution
Routes of administration	Intranasal use

Dosage and administration details:

4 UI per day

Arm title	arm 3 : 8 UI/day
------------------	------------------

Arm description:

children received 4UI two times per day

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Oxytocin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal drops, solution
Routes of administration	Intranasal use

Dosage and administration details:

4 UI per day

Number of subjects in period 1	arm 1 : 4UI every 2 days	arm2 : 4 UI/day	arm 3 : 8 UI/day
Started	6	6	6
Completed	5	6	5
Not completed	1	0	1
Adverse event, non-fatal	1	-	-
Lost to follow-up	-	-	1

Baseline characteristics

Reporting groups

Reporting group title	overall trial
-----------------------	---------------

Reporting group description:

18 infants less than 3 months old

Reporting group values	overall trial	Total	
Number of subjects	18	18	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	18	18	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
infants	0	0	
infants < 6 months	0	0	
Age continuous			
Age of infants recorded in months			
Units: months			
median	3.8		
full range (min-max)	1.0 to 6.0	-	
Gender categorical			
Units: Subjects			
Female	8	8	
Male	10	10	

Subject analysis sets

Subject analysis set title	Safety analysis
----------------------------	-----------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Safety was analysed by collecting adverse events

Reporting group values	Safety analysis		
Number of subjects	18		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		

Infants and toddlers (28 days-23 months)	18		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
infants	0		
infants < 6 months	0		
Age continuous			
Age of infants recorded in months			
Units: months			
median	3.8		
full range (min-max)	1.0 to 6.0		
Gender categorical			
Units: Subjects			
Female	8		
Male	10		

End points

End points reporting groups

Reporting group title	arm 1 : 4UI every 2 days
Reporting group description: children received 4UI of OT per day	
Reporting group title	arm2 : 4 UI/day
Reporting group description: children received 4UI/day of Oxytocin	
Reporting group title	arm 3 : 8 UI/day
Reporting group description: children received 4UI two times per day	
Subject analysis set title	Safety analysis
Subject analysis set type	Safety analysis
Subject analysis set description: Safety was analysed by collecting adverse events	

Primary: systemic adverse effects

End point title	systemic adverse effects ^[1]
End point description:	
End point type	Primary
End point timeframe: overall trial	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There was no systemic effects observed so no statistical analyses have been conducted.

End point values	arm 1 : 4UI every 2 days	arm2 : 4 UI/day	arm 3 : 8 UI/day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	6	6	6	
Units: numbers	10	9	6	

Statistical analyses

No statistical analyses for this end point

Secondary: NOMAS score

End point title	NOMAS score
End point description: NOMAS score evaluate sucking/swallowing abilities of infants during feeding; endpoint is the % of infants who reached a NOMAS score ≤ 10 (normal score)	
End point type	Secondary
End point timeframe: Before and after 7 days of treatment	

End point values	arm 1 : 4UI every 2 days	arm2 : 4 UI/day	arm 3 : 8 UI/day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	6	6	5	
Units: percentage	67	100	100	

Statistical analyses

No statistical analyses for this end point

Secondary: Videofluoroscopy of swallowing score (VFSS score)

End point title	Videofluoroscopy of swallowing score (VFSS score)
End point description: change from baseline (before treatment) of VFSS score	
End point type	Secondary
End point timeframe: before and after 7 days of treatment	

End point values	arm 1 : 4UI every 2 days	arm2 : 4 UI/day	arm 3 : 8 UI/day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	5	6	
Units: number				
arithmetic mean (standard deviation)	-5.2 (± 4.1)	-5.2 (± 2.7)	-4.8 (± 2.2)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

The investigator shall report to the sponsor, without delay from the date of knowledge, any serious adverse event.

The sponsor promptly reports unexpected AEs and developments during the course of the research.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	NA
--------------------	----

Reporting groups

Reporting group title	adverse event of study participants
-----------------------	-------------------------------------

Reporting group description: -

Serious adverse events	adverse event of study participants		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 18 (5.56%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Infections and infestations			
pneumonia	Additional description: Pneumonia with infectious focus on the left.		
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	adverse event of study participants		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 18 (100.00%)		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Gastrointestinal disorders			
Teething			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Gastroesophageal reflux disease			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Infantile colic			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hepatobiliary disorders			
Hepatobiliary injury			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hyperhidrosis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Lung infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Conjunctivis bacterial			

subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Urinary tract infection			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Oral candidiasis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 September 2013	Primary and secondary endpoints evaluation report following the 1st dose level. In order to be able to start the second step corresponding to 4 IU of oxytocin every day in one dose (i.e. 7 administrations) following the good progress of step 1 equivalent to 4 IU every 2 days in one dose (i.e. 4 administrations), we transmit you the results obtained on the 6 babies who participated in the first step. The research protocol, the information leaflet and the observation booklet are not modified.
03 March 2014	As for the 2nd level, the ANSM authorization is requested to start the third level by presentation of vigilance results of the second level.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/28100688>